LIVMARLI shows 70% risk reduction in Alagille syndrome

Published on 29 Feb 2024 on Investing.com

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM ) has released data indicating a significant improvement...

Read the rest of the article

Start tracking your investments with Statfolio

Key Insights Mirum Pharmaceuticals' Annual General Meeting to take place on 5th of JuneTotal pay ...

Simply Wall St. via Yahoo Finance 30 May 2024

With the business potentially at an important milestone, we thought we'd take a closer look at Mi...

Simply Wall St. via Yahoo Finance 28 May 2024

Mirum Pharmaceuticals, Inc. MIRM incurred first-quarter 2024 loss of 54 cents per share, wider th...

Zacks via Yahoo Finance 9 May 2024

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) recently announced the publication of the Phase 3...

Investing.com 7 May 2024

Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals Inc (NASDAQ:MIRM),...

GuruFocus.com via Yahoo Finance 26 Mar 2024

Mirum Pharmaceuticals, Inc. MIRM reported a fourth-quarter 2023 loss of 66 cents per share, wider...

Zacks via Yahoo Finance 1 Mar 2024

Mirum Pharmaceuticals, Inc. (ticker: NASDAQ:MIRM), a biopharmaceutical company dedicated to...

Investing.com 1 Mar 2024

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript February 28, 2024 Miru...

Insider Monkey via Yahoo Finance 1 Mar 2024

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM ) has released data indicating a significant improvemen...

Investing.com 29 Feb 2024

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.66 per share versus the Z...

Zacks via Yahoo Finance 28 Feb 2024